Shore Capital reaffirmed their hold rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report sent to investors on Friday, July 14th.
A number of other equities research analysts have also weighed in on GSK. Berenberg Bank lifted their price objective on shares of GlaxoSmithKline plc from GBX 1,850 ($24.40) to GBX 1,890 ($24.93) and gave the company a hold rating in a report on Friday, March 17th. J P Morgan Chase & Co reiterated a neutral rating and set a GBX 1,670 ($22.03) price objective on shares of GlaxoSmithKline plc in a report on Tuesday, March 21st. BNP Paribas reiterated an underperform rating and set a GBX 1,520 ($20.05) price objective on shares of GlaxoSmithKline plc in a report on Wednesday, March 22nd. Societe Generale restated a sell rating and issued a GBX 1,300 ($17.15) price target on shares of GlaxoSmithKline plc in a report on Thursday, March 23rd. Finally, Kepler Capital Markets restated a reduce rating and issued a GBX 1,500 ($19.79) price target on shares of GlaxoSmithKline plc in a report on Wednesday, March 29th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of GBX 1,731.62 ($22.84).
Shares of GlaxoSmithKline plc (GSK) opened at 1534.00 on Friday. The company’s 50-day moving average price is GBX 1,625.68 and its 200 day moving average price is GBX 1,626.10. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56. The company’s market cap is GBX 74.98 billion.
The business also recently disclosed a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.
In other GlaxoSmithKline plc news, insider Manvinder Singh Banga bought 2,267 shares of GlaxoSmithKline plc stock in a transaction dated Wednesday, July 26th. The stock was acquired at an average cost of GBX 1,599 ($21.09) per share, for a total transaction of £36,249.33 ($47,816.03). Also, insider Patrick Vallance bought 861 shares of GlaxoSmithKline plc stock in a transaction dated Friday, July 14th. The stock was acquired at an average price of GBX 1,618 ($21.34) per share, with a total value of £13,930.98 ($18,376.18). Insiders have acquired 3,150 shares of company stock valued at $5,054,075 over the last 90 days.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.
